Cargando…
Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
A significant fraction of non-small cell lung cancer (NSCLC) cases are due to oncogenic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Anti-EGFR antibodies have shown limited clinical benefit for NSCLC, whereas tyrosine kinase inhibitors (TKIs) are effective,...
Autores principales: | Thomas, Brian J., Guldenpfennig, Caitlyn, Guan, Yue, Winkler, Calvin, Beecher, Margaret, Beedy, Michaela, Berendzen, Ashley F., Ma, Lixin, Daniels, Mark A., Burke, Donald H., Porciani, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589377/ https://www.ncbi.nlm.nih.gov/pubmed/37869258 http://dx.doi.org/10.1016/j.omtn.2023.102046 |
Ejemplares similares
-
Cancer immunomodulation using bispecific aptamers
por: Thomas, Brian J., et al.
Publicado: (2022) -
Inhibition of Cell Proliferation by an Anti-EGFR Aptamer
por: Li, Na, et al.
Publicado: (2011) -
Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines
por: Porciani, David, et al.
Publicado: (2018) -
Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes
por: Tawiah, Kwaku D., et al.
Publicado: (2017) -
NF-kB’s contribution to B cell fate decisions
por: Guldenpfennig, Caitlyn, et al.
Publicado: (2023)